1-20 of 33
Maria Jure-Kunkel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3093: Molecular profiling of tisotumab vedotin-treated patients identified immune pathways associated with clinical activity, supporting the multimodal mechanism of action

Free
Sriram Sridhar, Guy Roukens, Christina Yu, Han Si, Steven Xu, Lauren Brady, Merzu Belete, Mark Bieda, Khyati N. Shah, Regina Aquino, Denise Gallagher, Brandon Higgs, Mark Fereshteh, Maria Jure-Kunkel, Jeffrey R. Harris
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 3093.
https://doi.org/10.1158/1538-7445.AM2025-3093
Published: 21 April 2025
View articletitled, Abstract 3093: Molecular profiling of tisotumab vedotin-treated patients identified immune pathways associated with clinical activity, supporting the multimodal mechanism of action
Journal Articles

Abstract 5788: Molecular profiling of NSCLC patients associates CT-based radiomic features with a tumor microenvironment favorable for immunotherapy

Free
Lauren K. Brady, Amogh Hiremath, Mohammed Qutaish, Kai Zhang, Kaustav Bera, Anant Madabhushi, Sri Sridhar, Nora Pencheva, Patricia Garrido-Castro, Maria Jure-Kunkel, Omar Jabado, Matthew Loya, Erin Henitz, Regina Aquino, Teng Jin Ong, Nathaniel Braman, Brandon W. Higgs
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 5788.
https://doi.org/10.1158/1538-7445.AM2025-5788
Published: 21 April 2025
View articletitled, Abstract 5788: Molecular profiling of NSCLC patients associates CT-based radiomic features with a tumor microenvironment favorable for immunotherapy
Journal Articles

Abstract 2587: Evaluating the potential of radiomics features to predict outcome to an antibody-drug conjugate therapy in non-small cell lung cancer patients

Free
Andrew W. Chen, Lauren K. Brady, Eric A. Cohen, Walter C. Mankowski, Leonid Roshkovan, Mohammed Qutaish, Sharyn Katz, Patricia G. Castro, Nora Pencheva, Maria Jure-Kunkel, Brandon W. Higgs, Despina Kontos
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2587.
https://doi.org/10.1158/1538-7445.AM2024-2587
Published: 22 March 2024
View articletitled, Abstract 2587: Evaluating the potential of radiomics features to predict outcome to an antibody-drug conjugate therapy in non-small cell lung cancer patients
Journal Articles

Abstract 3732: Peripheral pharmacodynamic activity of epcoritamab as monotherapy and in combination with rituximab + lenalidomide in patients with follicular lymphoma

Free
Han Si, Jimin Zhang, Monica Wielgos-Bonvallet, Lorenzo Falchi, Kim Linton, Wojciech Jurczak, David Belada, Işıl Altıntaş, Mariana Sacchi, Elena Favaro, Ali Rana, Daniela Hoehn, David Soong, Christopher W. Chiu, Maria Jure-Kunkel
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3732.
https://doi.org/10.1158/1538-7445.AM2024-3732
Published: 22 March 2024
View articletitled, Abstract 3732: Peripheral pharmacodynamic activity of epcoritamab as monotherapy and in combination with rituximab + lenalidomide in patients with follicular lymphoma
Journal Articles

Abstract 5071: Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE™ NHL-1 trial

Free
David Soong, Işıl Altıntaş, John Karavitis, Kim M. Linton, Wojciech Jurczak, Catherine Thieblemont, Kevin Zhao, Edith Szafer-Glusman, Daniela Hoehn, Elena Favaro, Mariana Sacchi, Maria Jure-Kunkel
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5071.
https://doi.org/10.1158/1538-7445.AM2024-5071
Published: 22 March 2024
View articletitled, Abstract 5071: Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE™ NHL-1 trial
Journal Articles

Abstract 3283: GEN1046 (DuoBody®-PD-L1x4-1BB) in combination with PD-1 blockade potentiates anti-tumor immunity

Free
Michela Capello, Angelica Sette, Theo Plantinga, Vanessa Spires, Kristina Nuermberger, Jordan Blum, Alexander Muik, Carol Costa Sa, Omar Jabado, Saskia Burm, Aras Toker, Sina Fellermeier-Kopf, Tahi Ahmadi, Brandon Higgs, Suzana Couto, Özlem Türeci, Mark Fereshteh, Ugur Sahin, Maria Jure-Kunkel, Nora Pencheva
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3283.
https://doi.org/10.1158/1538-7445.AM2023-3283
Published: 04 April 2023
View articletitled, Abstract 3283: GEN1046 (DuoBody®-PD-L1x4-1BB) in combination with PD-1 blockade potentiates anti-tumor immunity
Journal Articles

Abstract 3281: GEN1042 (DuoBody-CD40x4-1BB)®in combination with PD-1 blockade reverses T-cell exhaustion in vitro

Free
Vanessa M. Spires, Gregg Masters, Christina Yu, Matt Hancock, Monique N. Luijten, Alexander Muik, Kristina Nuermberger, Friederike Gieseke, Tahamtan Ahmadi, Özlem Türeci, Maria Jure-Kunkel, Ugur Sahin, Mark Fereshteh, Homer C. Adams, Jordan M. Blum
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3281.
https://doi.org/10.1158/1538-7445.AM2023-3281
Published: 04 April 2023
View articletitled, Abstract 3281: GEN1042 (DuoBody-CD40x4-1BB)®in combination with PD-1 blockade reverses T-cell exhaustion in vitro
Journal Articles

Abstract 3248: Pharmacodynamic activity of epcoritamab (GEN3013; CD3xCD20) as monotherapy is maintained in combination with standard of care therapies in patients with diffuse large B-cell lymphoma

Free
Jimin Zhang, Han Si, Monica Wielgos-Bonvallet, David Soong, Edith Szafer-Glusman, Herve Ghesquieres, Chan Y. Cheah, Lorenzo Falchi, Joshua Brody, Mariana Sacchi, Ali Rana, Brandon Higgs, Brian Elliot, Maria Jure-Kunkel, Christopher W. Chiu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3248.
https://doi.org/10.1158/1538-7445.AM2023-3248
Published: 04 April 2023
View articletitled, Abstract 3248: Pharmacodynamic activity of epcoritamab (GEN3013; CD3xCD20) as monotherapy is maintained in combination with standard of care therapies in patients with diffuse large B-cell lymphoma
Journal Articles

Abstract 2034: Spatial transcriptomics identifies unique pharmacodynamic effects of checkpoint inhibitor treatment on the tumor microenvironment in NSCLC

Free
Li Fan, Omar Jabado, Nora Pencheva, Patricia Coutinho de Souza, Brandon Higgs, Angelo Harris, Patrick Franken, Anantharaman Muthuswamy, Maria Jure-Kunkel, Suzana Couto, Kate Sasser, Mark Fereshteh
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2034.
https://doi.org/10.1158/1538-7445.AM2022-2034
Published: 15 June 2022
View articletitled, Abstract 2034: Spatial transcriptomics identifies unique pharmacodynamic effects of checkpoint inhibitor treatment on the tumor microenvironment in NSCLC
Journal Articles

Abstract 1574: Preclinical evaluation of epcoritamab combined with standard of care therapies for the treatment of B-cell lymphomas

Free
Christopher W. Chiu, Ida H. Hiemstra, Wessel ten Hagen, Rajaa Snijdewint-Nkairi, Bart de Jong, Roberto S. Oliveri, Brian Elliot, Edith Szafer-Glusman, Danita Schuurhuis, Julie Blaedel, Tahamatan Ahmadi, Esther Breij, A. Kate Sasser, Maria Jure-Kunkel
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1574.
https://doi.org/10.1158/1538-7445.AM2021-1574
Published: 01 July 2021
View articletitled, Abstract 1574: Preclinical evaluation of epcoritamab combined with standard of care therapies for the treatment of B-cell lymphomas
Journal Articles

Abstract 1846: DuoBody-CD40×4-1BB (GEN1042) induces dendritic-cell maturation and enhances T-cell activation and effector functions in vitro by conditional CD40 and 4-1BB agonist activity

Free
Alexander Muik, Rachelle Kosoff, Friederike Gieseke, Isil Altintas, Kristina Schödel, Saskia Burm, Eliana Stanganello, Fulvia Vascotto, Aras Toker, Homer Adams, III, Esther Breij, Mustafa Diken, Tahamtan Ahmadi, Kate Sasser, Özlem Türeci, Mark Fereshteh, Ugur Sahin, Maria Jure-Kunkel
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1846.
https://doi.org/10.1158/1538-7445.AM2021-1846
Published: 01 July 2021
View articletitled, Abstract 1846: DuoBody-CD40×4-1BB (GEN1042) induces dendritic-cell maturation and enhances T-cell activation and effector functions in vitro by conditional CD40 and 4-1BB agonist activity
Journal Articles

Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade

Available to Purchase
Julia Boshuizen, Nora Pencheva, Oscar Krijgsman, Daniela D'Empaire Altimari, Patricia Garrido Castro, Beaunelle de Bruijn, Maarten A. Ligtenberg, Elke Gresnigt-Van den Heuvel, David W. Vredevoogd, Ji-Ying Song, Nils Visser, Georgi Apriamashvili, Maarten L. Janmaat, Theo S. Plantinga, Patrick Franken, Mischa Houtkamp, Andreas Lingnau, Maria Jure-Kunkel, Daniel S. Peeper
Journal: Cancer Research
Cancer Res (2021) 81 (7): 1775–1787.
https://doi.org/10.1158/0008-5472.CAN-20-0434
Published: 01 April 2021
View articletitled, Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade
Open the PDF for Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade in another window
Includes: Supplementary data
Journal Articles

Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice

Free
Ayumi Hashimoto, Chan Gao, Jerome Mastio, Andrew Kossenkov, Scott I. Abrams, Ashok V. Purandare, Heshani Desilva, Susan Wee, John Hunt, Maria Jure-Kunkel, Dmitry I. Gabrilovich
Journal: Cancer Research
Cancer Res (2018) 78 (19): 5644–5655.
https://doi.org/10.1158/0008-5472.CAN-18-1229
Published: 01 October 2018
View articletitled, Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice
Open the PDF for Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice in another window
Includes: Supplementary data
Journal Articles

Abstract 2776: MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells

Free
Simon J. Dovedi, Yariv Mazor, Matthew Elder, Sumati Hasani, Bo Wang, Suzanne Mosely, Desmond Jones, Anna Hansen, Chuning Yang, Yanli Wu, Ikbel Achour, Nick Durham, Gareth Browne, Thomas Murray, James Hair, Michelle Morrow, Godfrey Rainey, Maria Jure Kunkel, John Gooya, Daniel Freeman, Ronald Herbst, Robert Wilkinson
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2776.
https://doi.org/10.1158/1538-7445.AM2018-2776
Published: 01 July 2018
View articletitled, Abstract 2776: MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells
Journal Articles

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming

Free
María E. Rodriguez-Ruiz, Inmaculada Rodriguez, Saray Garasa, Benigno Barbes, Jose Luis Solorzano, Jose Luis Perez-Gracia, Sara Labiano, Miguel F. Sanmamed, Arantza Azpilikueta, Elixabet Bolaños, Alfonso R. Sanchez-Paulete, M. Angela Aznar, Ana Rouzaut, Kurt A. Schalper, Maria Jure-Kunkel, Ignacio Melero
Journal: Cancer Research
Cancer Res (2016) 76 (20): 5994–6005.
https://doi.org/10.1158/0008-5472.CAN-16-0549
Published: 13 October 2016
View articletitled, Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming
Open the PDF for Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming in another window
Includes: Supplementary data
Journal Articles

Abstract 4908: Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires Batf3-dependent dendritic cells

Free
Alfonso R. Sánchez-Paulete, Francisco J. Cueto, María Martínez-López, Sara Labiano, Aizea Morales-Kastresana, Maria E. Rodríguez-Ruiz, Maria Jure-Kunkel, Arantza Azpilikueta, José I. Quetglas, David Sancho, Ignacio Melero
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4908.
https://doi.org/10.1158/1538-7445.AM2016-4908
Published: 15 July 2016
View articletitled, Abstract 4908: Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires Batf3-dependent dendritic cells
Journal Articles

Abstract 4012: Improving radiotherapy abscopal effects with anti-PD1 and anti-CD137-based immunotherapy

Free
MariaE. Rodríguez-Ruiz, Inmaculada Rodriguez, Saray Garasa, Benigno Barbes, Jose Luis Solorzano, Jose Luis Perez Gracia, Sara Labiano, Arantza Azpilikueta, Elixabet Bolanos, Alfonso R. Sanchez-Paulete, M. Angela Aznar, Ana Rouzaut, Maria Jure-Kunkel, Iñaki Etxeberria, Carlos Alfaro, Carmen Oñate, Mariano Ponz, Ignacio Melero
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4012.
https://doi.org/10.1158/1538-7445.AM2016-4012
Published: 15 July 2016
View articletitled, Abstract 4012: Improving radiotherapy abscopal effects with anti-PD1 and anti-CD137-based immunotherapy
Journal Articles

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice

Free
Miguel F. Sanmamed, Inmaculada Rodriguez, Kurt A. Schalper, Carmen Oñate, Arantza Azpilikueta, Maria E. Rodriguez-Ruiz, Aizea Morales-Kastresana, Sara Labiano, Jose L. Pérez-Gracia, Salvador Martín-Algarra, Carlos Alfaro, Guillermo Mazzolini, Francesca Sarno, Manuel Hidalgo, Alan J. Korman, Maria Jure-Kunkel, Ignacio Melero
Journal: Cancer Research
Cancer Res (2015) 75 (17): 3466–3478.
https://doi.org/10.1158/0008-5472.CAN-14-3510
Published: 31 August 2015
View articletitled, Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice
Open the PDF for Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice in another window
Includes: Supplementary data
Journal Articles

Abstract 1306: Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC)

Free
Toni K. Choueiri, Mayer N. Fishman, Bernard Escudier, Walter M. Stadler, Scott Chasalow, Petra Ross-Macdonald, Maria Jure-Kunkel, Mario Sznol, Jason S. Simon
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1306.
https://doi.org/10.1158/1538-7445.AM2015-1306
Published: 01 August 2015
View articletitled, Abstract 1306: Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC)
Journal Articles

Abstract 261: Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice

Free
Miguel F. Sanmamed, Inmaculada Rodriguez, Carmen Oñate, Arantza Azpilikueta, Maria E. Rodriguez-Ruiz, Aizea Morales-Kastresana, Sara Labiano, Jose L. Perez-Gracia, Salvador Martín-Algarra, Carlos Alfaro, Kurt A. Schalper, Guillermo Mazzolini, Francesca Sarno, Manuel Hidalgo, Alan J. Korman, Maria Jure-Kunkel, Ignacio Melero
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 261.
https://doi.org/10.1158/1538-7445.AM2015-261
Published: 01 August 2015
View articletitled, Abstract 261: Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice